Congratulations to @TraceNeuro on their launch with a $101M Series A! We are excited to support a team on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases.
1 in 400 people around the world will be diagnosed w/ #ALS in their lifetime. Meet Trace - on a mission to expand the promise of genomic medicine for those w/ neurodegenerative diseases, re-establishing healthy communication between nerves & muscle cells. businesswire.com/news/home/2…
Great news for the @AbataTx team, patients, and their families!
This Post is from an account that no longer exists. Learn more
Congrats to the @moma_tx team! One step closer to helping oncology patients.
The 1st patient has been dosed in the Phase 1 clinical trial of MOMA-313, a novel, highly potent & selective oral POLq helicase inhibitor, & we've selected our 2nd development candidate, MOMA-341, an oral Werner helicase inhibitor. Read & learn more: businesswire.com/news/home/2…
Congratulations to Arnav Mehta for receiving the 2024 NextGen Stars award from AACR. So well deserved!
@arnavmehta3
This Post is from an account that no longer exists. Learn more
We are delighted to announce the expansion of our senior team!
thirdrockventures.com/upload…
Third Rock Ventures retweeted
And we’re live! Check out the very first episode of our new podcast: Moving Forward, Giving Back. On today’s show, we highlight our 2023 Impact Award Winners - exploring the ways they use the LSC model to support their communities. Tune in here: lifesciencecares.org/podcast…!
Congrats to the team at @bluebirdbio ! Exciting news for patients and their families
#NewsfromtheNest: We are thrilled to announce that the @US_FDA has approved our first gene therapy for patients ages 12 and older living with sickle cell disease who have a history of vaso-occlusive events. Read more in our press release: investor.bluebirdbio.com/new… [1/1]
We had our first farmers market last week in our office to raise money for @LS_Cares and the Hope Lodge - @AmericanCancer! It was a fun time with tasty food to support two great causes.
Our collaboration with BrightEdge broadens the impact we can have across the oncology ecosystem. You can learn more about the great work they do below.
BrightEdge is poised to impact the lives of over 1.5 million cancer patients through investments in cancer-focused therapies and technologies. To learn more, read the annual report: cancer.org/brightedge
Third Rock is proud to partner with such an impactful organization!
Thanks to an incredible list of sponsors and donors, the 2023 #TimmermanTraverse team has cracked their goal of raising $1M to support Life Science Cares' work in the community. And now they're aiming to see just how high they can go! Read more at lnkd.in/giSJ3eH2.
Congratulations! Great news for mothers and families.
BREAKING: The FDA has approved our new treatment, developed with @biogen, for women with #postpartumdepression. Learn more: bit.ly/3Ymot5j
Congratulations to the team at @Septerna_Inc !
Today we announced a $150M Series B financing, enabling the advancement of our lead program to clinical proof-of-mechanism and marking an important transition for our company. Read today’s news: ow.ly/LAxo50P8qoE
We had the pleasure of hosting an inspiring fireside chat with @TracyDixonSalaz and Brad Galer about rare epilepsies and Lennox-Gastaut Syndrome and the high unmet medical need in the precision neuromedicine space.
Please join us in welcoming Mary Lynne Hedley to TRV as our newest Venture Partner. She brings valuable leadership and strategic insight across R&D, operations, corporate strategy and business development. We are excited to have her as part of the team!
IgniteVC, a new initiative from @IgniteLC in partnership with @BioscienceGroup, has launched to accelerate DEI in life sciences VCs and their portfolio companies by offering practical tools, best practices, and a community of peers.
Congrats to Rapport Therapeutics on the announcement of their launch with a $100 million Series A financing. Rapport is dedicated to the discovery and development of precision medicines for neurological disorders and we are excited to be a part of it! rapportrx.com/2023/03/07/rap…
We are excited to be a Founding Partner in the expansion of @ProjectOnramp w/@LS_Cares to support + create paid summer internships for students who are under-resourced and under-represented, helping to bridge the opportunity gap into our industry.
We’re on a mission to scale @ProjectOnramp to reach 1,000 students around the country each summer by 2027. Thanks to @ThirdRockV for this multi-year commitment to help us get there! bostonglobe.com/2023/02/06/b…
